109 related articles for article (PubMed ID: 3134315)
1. Comparative study of alloimmune reactions induced by leukocyte and platelet transfusions in humans: characteristic changes of activation markers, gamma interferon, and FcR blocking antibody production.
Kotlán B; Gyódi E; Szabó T; Takács K; Troppmair J; Petri I; Padányi A; Kaiser G; Kassai M; Huber C
Hum Immunol; 1988 May; 22(1):19-29. PubMed ID: 3134315
[TBL] [Abstract][Full Text] [Related]
2. Differences in non-MHC restricted cytotoxic activities of human peripheral blood lymphocytes after transfusion with allogeneic leukocytes or platelets possessing class I and/or class II MHC molecules.
Pócsik E; Mihalik R; Réti M; Gyódi E; Pálóczi K; Mayer K; Kassai M; Herold M; Huber C; Petrányi GG
Immunobiology; 1990 Dec; 182(1):22-31. PubMed ID: 1983002
[TBL] [Abstract][Full Text] [Related]
3. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
Front Immunol; 2018; 9():1251. PubMed ID: 29951051
[TBL] [Abstract][Full Text] [Related]
4. Selective effect of noncytotoxic blocking alloantibodies produced after platelet transfusions on MLC, and mitogen and soluble antigen-induced responses of human lymphocytes.
Horuzsko A; Gyódi E; Réti M; Mayer K; Kassay M; Petrányi G
Transplantation; 1990 Sep; 50(3):497-501. PubMed ID: 2144926
[TBL] [Abstract][Full Text] [Related]
5. Functional and immunogenetic characterization of FcR-blocking antibody.
Padányi A; Gyódi E; Sarmay G; Réti M; Mayer K; Kassai M; Petrányi GG
Immunol Lett; 1990 Nov; 26(2):131-7. PubMed ID: 2269483
[TBL] [Abstract][Full Text] [Related]
6. Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, a selective inhibitor of inducible nitric oxide synthase.
Bang A; Speck ER; Blanchette VS; Freedman J; Semple JW
Blood; 1996 Oct; 88(8):2959-66. PubMed ID: 8874192
[TBL] [Abstract][Full Text] [Related]
7. Mixed lymphocyte culture--evidence that pretransplant transfusion with platelets induces FcR and blocking antibody production similar to that induced by leukocyte transfusion.
Petrányi GG; Padányi A; Horuzsko A; Rethy M; Gyódi E; Perner F
Transplantation; 1988 Apr; 45(4):823-4. PubMed ID: 2965837
[No Abstract] [Full Text] [Related]
8. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
[TBL] [Abstract][Full Text] [Related]
9. Alloimmunization by leukocyte-rich or leukocyte-poor random single donor platelets.
Gmür J; Burger J; Sauter C; Oelz O; Frick PG
Prog Clin Biol Res; 1990; 337():45-8. PubMed ID: 2191337
[No Abstract] [Full Text] [Related]
10. An experimental model for preventing alloimmunization against platelet transfusions by pretreatment with antibody-coated cells.
Süsal C; Terness P; Opelz G
Vox Sang; 1990; 59(4):209-15. PubMed ID: 2293460
[TBL] [Abstract][Full Text] [Related]
11. Induction of humoral immune tolerance to major histocompatibility complex antigens by transfusions of UVB-irradiated leukocytes.
Kao KJ
Blood; 1996 Dec; 88(11):4375-82. PubMed ID: 8943875
[TBL] [Abstract][Full Text] [Related]
12. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.
Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG
Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645
[TBL] [Abstract][Full Text] [Related]
13. [Formation of anti-leukocyte antibody and anti-platelet antibody and its effects on blood component transfusion].
Shimoyama M; Minato K; Ideura Y; Kimura K
Nihon Rinsho; 1977 Dec; 35(12):4146-54. PubMed ID: 342757
[No Abstract] [Full Text] [Related]
14. Prevention of platelet alloimmunization.
Slichter SJ
Prog Clin Biol Res; 1986; 211():83-116. PubMed ID: 3515365
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated inhibition of the human alloimmune response to platelet transfusion in Hu-PBL-SCID mice.
Crow AR; Freedman J; Hannach B; Blanchette V; Lazarus AH
Br J Haematol; 1999 Mar; 104(4):919-24. PubMed ID: 10192460
[TBL] [Abstract][Full Text] [Related]
17. Non-cytotoxic blocking antibodies and suppressor cells induced by donor-specific transfusions in healthy volunteers and potential kidney transplant recipients.
Horuzsko A; Gyódi E; Réti M; Onody K; Perner F; Kassay M; Petrányi GG
Immunol Lett; 1990 Nov; 26(2):127-30. PubMed ID: 2148542
[TBL] [Abstract][Full Text] [Related]
18. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions.
Fisher M; Chapman JR; Ting A; Morris PJ
Vox Sang; 1985; 49(5):331-5. PubMed ID: 3909636
[TBL] [Abstract][Full Text] [Related]
19. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model.
Slichter SJ; Pellham E; Bailey SL; Christoffel T; Gettinger I; Gaur L; Latchman Y; Nelson K; Bolgiano D
Blood; 2017 Aug; 130(8):1052-1061. PubMed ID: 28705838
[TBL] [Abstract][Full Text] [Related]
20. The polymorphic human TLX-B/CD46/MCP system and its implications in transplantation and reproduction.
Petrányi G; Padányi A; Szelényi J; Sármay G; Gyódi E; Fülöp V; Kassai M; Illés P; Réti M; Szigetvári I
Eur J Immunogenet; 1995 Apr; 22(2):147-61. PubMed ID: 7605772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
